Main Menu

Supporting Research. Empowering Families.

TAS-102 study for the treatment of metastatic stomach cancer.

This is a clinical research trial of TAS-102, which is the drug under investigation for the treatment of metastatic stomach cancer. This means that TAS-102 has not been approved for use in the country of your residence and/or for use in subjects with your particular diagnosis, except in a clinical research trial. TAS-102, under the brand name Lonsurf® (trifluridine and tipiracil), was approved in the U.S. on 22 September 2015 for the treatment of patients with metastatic colorectal cancer.

View and download more information on this study here.

Study for Those with or at Risk for Hereditary Stomach Cancer
 
Researchers at the National Institutes of Health (NIH) seek individuals with hereditary stomach (gastric) cancer or who are at risk for developing stomach cancer because of a genetic (inherited) condition. Hereditary stomach cancers run in families, meaning they are passed from one generation to the next. In this study, we want to learn more about these types of stomach cancers as well as investigate the genes involved.
 
View and download more information on this study here.